Navigation Links
Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion
Date:11/8/2010

NEW YORK, Nov. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Commercial Insight: Antihormonal Cancer Therapies - Leading brands strive to minimize generic sales erosion

http://www.reportlinker.com/p0255121/Commercial-Insight-Antihormonal-Cancer-Therapies---Leading-brands-strive-to-minimize-generic-sales-erosion.html

IntroductionAntihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $7.0 billion in the seven major pharmaceutical markets in 2009.

Scope*In-depth analysis of the current and future antihormonal therapies market across the US, 5EU and Japan, plus a rest of world snapshot

*Antihormonal therapy sales forecasts for brands and generics from 2009 to 2019

*Assessment of the leading cancer brands and drug classes to identify key success factors within this sector

*Evaluation of the strategies of leading players in the antihormonals market

HighlightsThe antihormonals market was worth $7.0 billion in 2009 across the seven major pharmaceutical markets. Datamonitor forecasts the antihormonals market will shrink marginally in the forecast period 20092019, at a CAGR of negative 0.7%.

In 2019 the top three brands in terms of forecast sales will be Arimidex, Lupron (leuprolide; Takeda/Abbott) and Casodex (bicalutamide; AstraZeneca). Despite losing around 54% of its current sales value to generic competitors, Arimidex will retain its market leading position.

In a mature market, the importance of product lifecycle management is high. AstraZeneca was the key player in the market in 2009, with an antihormonals portfolio valued at over $3.2 billion. With successful lifecycle management and a considerable investment in marketing activities, AstraZeneca has built a strong brand presence for its products.

Reasons to Purchase*Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2009 to 2019

*Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth

*Benchmark antihormonal therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot

OVERVIEW 1

Catalyst 1

Summary 1

About Datamonitor healthcare 2

About the Oncology pharmaceutical analysis team 2

EXECUTIVE SUMMARY 3

Strategic scoping and focus 3

Datamonitor insight into the antihormonal cancer therapies market 3

Related reports 4

Upcoming related reports 4

Table of Contents 5

MARKET DEFINITION 6

Definition of the cancer market 6

Antihormonal therapies by ATC class 6

L2A3 - Luteinizing hormone-releasing hormone agonists 6

L2B1 - Anti-estrogens 7

L2B2 - Anti-androgens 7

L2B3 - Aromatase inhibitors 7

L2B9 - Other hormone antagonists 7

MARKET OVERVIEW 9

Seven major markets 10

Current and future market overview 10

The antihormonals market will shrink marginally in the forecast period 10

Patent expiries of leading antihormonal brands are set to occur within the next 5 years 10

The US will suffer the greatest impact of generic erosion, losing around 25% of its value over the forecast period 12

The aromatase inhibitors will continue to be the leading drug class in 2019 13

The current leading antihormonal brands will suffer generic sales erosion but will maintain a high level of sales 14

The antihormonal therapies market will shrink from $7.0 billion in 2009 to $6.5 billion in 2019 across the seven major pharmaceutical markets 15

Opportunities and threats 17

Opportunity 1: aging population will result in increasing cancer incidence 17

Opportunity 2: oncology therapy sales continue to experience strong growth 18

Opportunity 3: high levels of unmet need 19

Threat 1: Pharma's transition towards specialist secondary care indications may further competition in the oncology market 20

Threat 2: the cost of drug development continues to rise 20

Threat 3: ongoing cost-containment measures 20

US 21

Current and future market assessment 21

The US antihormonals market will suffer the greatest impact of generic sales erosion 21

Opportunities and threats 25

Opportunity 1: the US's large population and high healthcare expenditure will continue to offer commercial opportunities for drug developers 25

Opportunity 2: healthcare reform will boost the number of insured in the US 25

Opportunity 3: closure of the Medicare Part D coverage gap is good news for branded Pharma 26

Threat 1: growing regulatory pressures increase costs and decrease market penetration for Pharma 26

Threat 2: patent expiries and the resulting generic competition will erode branded sales revenues 27

Threat 3: the US health reform law will intensify cost-containment pressures 27

Japan 28

Current and future market assessment 28

The antihormonals market in Japan is forecast to grow over the forecast period 28

Opportunities and threats 32

Opportunity 1: the aging population represents a large and growing patient base 32

Opportunity 2: generic sales erosion remains low in Japan 32

Opportunity 3: decrease in lag times for launch of new drugs could accelerate new launches 33

Threat 1: government-enforced biennial cuts continue to have a negative effect on market growth 33

Threat 2: healthcare proposal to change current pricing system will be of limited benefit to Japanese Pharma 34

Threat 3: encouraging decrease in lag times for launch of new drugs 34

Five major European markets (5EU) 36

Current and future market assessment 36

The antihormonals therapies market in the five European countries will show marginal growth 36

The antihormonal therapies market will grow from $2.6 billion in 2009 to $2.7 billion in 2019 in the five major European markets 38

Opportunities and threats 40

Opportunity 1: EU Cancer Task Force will improve the availability of information while generating funds for research 41

Opportunity 2: reorganization of the European Medicines Agency (EMA) expected to streamline EU regulatory process 41

Threat 1: new European drug price reductions are likely to affect pharma industry growth 41

Threat 2: higher generic uptake in less mature EU markets will impact branded sales revenues 42

Threat 3: EC inquiry into delays in generics market entry will have wide-ranging ramifications for the branded and generics industry 43

Threat 4: Spain's price cuts and reference groups are driving drug prices down 44

Threat 5: new low reimbursement rate created in France signals the growing pressure for cost-containment 44

Threat 6: NICE will remain a significant hurdle to commercialization of cancer drugs in the UK, despite relaxation of its cost-effectiveness criteria 45

Threat 7: Germany's new cost-effectiveness analysis system could add to the downward pressure on drug prices 46

Threat 8: additional cuts to the price of oncology drugs in Italy are impending under its pay-for-performance scheme 47

France 48

Current and future market assessment 48

The antihormonal therapies market in France will peak at around $654m in 2010. 48

Germany 51

Current and future market assessment 51

The antihormonals therapies market will grow from $727m in 2009 to $835m in 2019 in Germany 51

Italy 55

Current and future market assessment 55

The antihormonal therapies market will grow from $484m in 2009 to $512m in 2019 in Italy 55

Spain 58

Current and future market assessment 58

The antihormonals market in Spain will marginally shrink from $418m in 2009 to $396m in 2019 in Spain 58

UK 61

Current and future market assessment 61

The antihormonal therapies market will grow from $333m in 2009 to $348m in 2019 in the UK 61

Rest of the world snapshot 65

Current market assessment 65

Rest of the world sales represent 18% of the global antihormonals market 65

Opportunities and threats 66

Opportunity 1: incidence of cancer is forecast to increase in the BRIC countries 66

Opportunity 2: emerging markets continue to attract pharma companies despite challenges 67

Threat 1: cost of new therapies is a barrier to market penetration 67

BRAND DYNAMICS 68

Overview of competitive landscape 68

Arimidex, Lupron and Casodex will be the top three antihormonal brands in 10 years time 68

Drivers of brand choice 69

Efficacy and toxicity are the most important drivers of brand choice 69

Trends in marketing strategies 70

Marketing strategy for leading brands 70

Patient information and support programs 71

Direct-to-consumer advertising 73

Arimidex (anastrozole; AstraZeneca) 74

Drug profile 75

Product positioning 75

SWOT analysis 76

Brand forecast to 2019 77

Arimidex set to lose 54% of its current sales value to generic competitors 77

Lupron (leuprolide; Takeda/Abbott) 81

Drug profile 81

Product positioning 81

SWOT analysis 83

Brand forecast to 2019 83

Lupron will be the top selling antihormonal therapy in 2019, with sales in excess of $1 billion 83

Casodex (bicalutamide; AstraZeneca) 85

Drug profile 86

Product positioning 86

SWOT analysis 87

Brand forecast to 2019 88

Patent expiries set to hamper sales of this class-leading brand 88

KEY DEVELOPERS 90

Strategic overview 90

Trends in corporate strategy 91

Strategic lifecycle management is essential in the antihormonals market 91

Commercialization partnerships are common for smaller players 91

AstraZeneca 91

Corporate strategy 91

Oncology antihormonals portfolio assessment 92

Takeda 93

Corporate strategy 93

Oncology antihormonals portfolio assessment 93

Portfolio assessment of other leading companies 94

BIBLIOGRAPHY 96

Journal papers 96

Websites 96

Datamonitor reports 101

Other 102

APPENDIX A - MARKET ASSUMPTIONS 103

Forecasting assumptions 103

New product launches 103

Patent expiries 103

Data definitions, limitations and assumptions 104

Standard units 104

Country group definitions 104

Rest of the World 104

The 'all other EU countries' group 104

The 'Other non-EU countries' group 104

Forecast methodology 105

Derivation of sales forecasts and pricing trends 105

Exchange rates 105

Report methodology 106

APPENDIX B 107

About Datamonitor 107

About Datamonitor Healthcare 107

About the Oncology analysis team 108

Disclaimer 110

List of Tables Table 1: Definition of the cancer market, 2010 6

Table 2: Sales and growth of antihormonal therapy drug classes in the seven major pharmaceutical markets ($m), 2009-2019 10

Table 3: Key events impacting the antihormonal therapies market in the seven major markets, 2009-2019 11

Table 4: Antihormonal therapy sales forecasts in the seven major markets ($m), 2009-2019 16

Table 5: Summary of opportunities and threats that will impact the antihormonals market across the seven major markets, 2009-2019 17

Table 6: Sales and growth of antihormonal therapy drug classes in the US ($m), 2009-2019 21

Table 7: Top 5 branded antihormonals in the US in 2009 and 2019 23

Table 8: Antihormonal therapy sales forecasts in the US ($m), 2009-2019 24

Table 9: Summary of opportunities and threats to impact the antihormonals market in the US, 2009-2019 25

Table 10: Sales and growth of antihormonal therapy drug classes in Japan ($m), 2009-2019 28

Table 11: Top 5 branded antihormonals in Japan in 2009 and 2019 30

Table 12: Antihormonal therapy sales forecasts in Japan ($m), 2009-2019 31

Table 13: Summary of opportunities and threats to impact the antihormonals market in Japan, 2009-2019 32

Table 14: Sales and growth of antihormonal therapy drug classes in the five major EU markets ($m), 2009-2019 36

Table 15: Top 5 branded antihormonals in the five major EU markets in 2009 and 2019 38

Table 16: Antihormonal therapy sales forecasts in the five major EU markets ($m), 2009-2019 39

Table 17: Summary of opportunities and threats to impact the antihormonals market in the five major EU markets, 2009-2019 40

Table 18: Risk-sharing agreements between NICE and selected pharma companies in the UK, 2009-2010 46

Table 19: Sales and growth of antihormonal therapy drug classes in France ($m), 2009-2019 48

Table 20: Top 5 branded antihormonals in France in 2009 and 2019 49

Table 21: Antihormonal therapy sales forecasts in France ($m), 2009-2019 50

Table 22: Sales and growth of antihormonal therapy drug classes in Germany ($m), 2009-2019 51

Table 23: Top 5 branded antihormonals in Germany in 2009 and 2019 53

Table 24: Antihormonal therapy sales forecasts in Germany ($m), 2009-2019 54

Table 25: Sales and growth of antihormonal therapy drug classes in Italy ($m), 2009-2019 55

Table 26: Top 5 branded antihormonals in Italy in 2009 and 2019 56

Table 27: Antihormonal therapy sales forecasts in Italy ($m), 2009-2019 57

Table 28: Sales and growth of antihormonal therapy drug classes in Spain ($m), 2009-2019 58

Table 29: Top 5 branded antihormonals in Spain in 2009 and 2019 59

Table 30: Antihormonal therapy sales forecasts in Spain ($m), 2009-2019 60

Table 31: Sales and growth of antihormonal therapy drug classes in the UK ($m), 2009-2019 61

Table 32: Top 5 branded antihormonals in the UK in 2009 and 2019 63

Table 33: Antihormonal therapy sales forecasts in the UK ($m), 2009-2019 64

Table 34: Comparison of antihormonal drug class sales in the US, Japan, five major EU markets and Rest of the world markets ($m), 2009 66

Table 35: Leading branded antihormonal therapy drug sales in the seven major markets ($m), 2009-2019 68

Table 36: Marketing strategies employed by companies behind the top three antihormonal brands, 2010 71

Table 37: Arimidex (anastrozole) - drug profile, 2010 75

Table 38: Factors impacting revenues of Arimidex, 2009-2019 79

Table 39: Lupron (leuprolide) - drug profile, 2010 81

Table 40: Factors impacting the revenues of Lupron, 2009-2019 85

Table 41: Casodex (bicalutamide) - drug profile, 2010 86

Table 42: Factors impacting the revenues of Casodex, 2009-2019 89

Table 43: Leading companies in the antihormonals market in the seven major pharmaceutical markets ($m), 2009-2019 90

Table 44: Assessment of AstraZeneca's cancer antihormonals portfolio, 2010 92

Table 45: Assessment of Takeda's cancer antihormonals portfolio, 2010 93

Table 46: Assessment of Novartis's cancer antihormonals portfolio, 2010 94

Table 47: Assessment of Pfizer's cancer antihormonals portfolio, 2010 94

Table 48: Assessment of Sanofi-Aventis's cancer antihormonals portfolio, 2010 95

Table 49: Regional launch dates for new antihormonals in the seven major markets, 2010-2019 103

Table 50: Patent expiry dates for the approved antihormonals in the seven major pharmaceutical markets, 2010-2019 103

List of Figures

Figure 26: Methodology for forecasting price to remove impact of currency fluctuations on future trend 105

To order this report:Therapy Industry: Commercial Insight: Antihormonal Cancer Therapies - Leading brands strive to minimize generic sales erosion

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs
2. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
3. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
4. High Unemployment Rates in North Carolina Will Continue to Dictate the Decrease of Commercial Health Plan Enrollment and the Increase of Medicaid Enrollment
5. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
6. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
7. Biocon and Pfizer Enter Into Global Commercialization Agreement
8. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
9. OLIGOMERIX, Inc. Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer
10. IRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe® Device for Eye Surgery
11. Concentric Medical Announces Commercial Launch of Trevo™ in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... , ... June 27, 2016 , ... Quality metrics are ... in many ways they remain in the eye of the beholder, according to experts ... publication of The American Journal of Managed Care. For the full issue, click ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):